GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1×1 meetings at the following investor conferences:
-
H.C. Wainwright 3
rd
Annual BioConnect Investor Conference (New York, NY)
Tuesday, May 20, 2025
Fireside Chat at 10:00 a.m. Eastern Time
-
Jefferies Global Healthcare Conference (New York, NY)
Wednesday, June 4, 2025
Fireside Chat at 9:55 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedIn
Follow @AltimmuneInc on
X
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
[email protected]
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]
Media Contact:
Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
[email protected]
This press release was published by a CLEAR® Verified individual.
